[go: up one dir, main page]

TW492876B - New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture - Google Patents

New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture Download PDF

Info

Publication number
TW492876B
TW492876B TW084108225A TW84108225A TW492876B TW 492876 B TW492876 B TW 492876B TW 084108225 A TW084108225 A TW 084108225A TW 84108225 A TW84108225 A TW 84108225A TW 492876 B TW492876 B TW 492876B
Authority
TW
Taiwan
Prior art keywords
cyclosporine
pharmaceutical composition
item
weight
patent scope
Prior art date
Application number
TW084108225A
Other languages
English (en)
Inventor
Matthias Olbrich
Heinrich Potter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of TW492876B publication Critical patent/TW492876B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Description

492876 A7 _B7 _ 五、發明說明(/ ) / …一 本發阴係關於環孢靈,特別是環孢靈A ,對於口服施 周所包含的液體配方。 環孢靈是由徵生耢所產生之天然的環狀胜M e 環®靈 中最重要的代表是環孢靈A ,它被用在擷制器官排斥的移 植治療和骨髓移植上。環孢靈A的徵生®產物及分離和純 化至非结晶無色粉末,其本質上已在德國專利案24 5 Γ— Ο Γ-* ΓΛ r+t +FT .
ο ο o ^ m m :J 環抱靈A 越來越多被周在自體免疫疾病的處理上 5 例牛皮癖(P s 〇 r i a s i s), 葡萄膜炎(u n e i t i s ), 賢病變症 候群(nephrotic syndronOM 及其飽 0 環孢靈的抗發炎及抗寄生蟲的特性也被描逑。 因為環孢靈疏水性的特性,要產生造戚此活性成份高 度生物可利周性的製藥組成是很困難的。實際上,已知的 _量型式顯示S在藥理動力學變數上招當廣的儒體肉和假 體間變異t生·。在招同的謂量時,Μ疲内環31靈的量在不同 病入閭的變異可達到5 0 %。即使在一儷相同的病人内其 吸牧量的變異&很大c但是,免疫抑制的治療依賴在爾量 依賴副作周和移植器官排斥之間相當窄的治療窗中。 不好的生物利羯搜乃特別歸因於環孢靈在包含水的颚 量形式混合物中的低溶解度。 有很多入企圖去解決這些製藥上的問題。 已知且商業上可提供的謂量形式為親脂性和親水性溶 麵的複雜条統和可溶的清潔劑,並帶有溶解環孢靈和保持 本纸張尺度適周中國國家標準(CNS)A4規格(210 X 297公釐〉 (請先閱讀背面之注意事項再填寫本頁)
492876 A7 B7 五、發明說明( V)
它們在 />α «-Ρ· ΛΛτ* m m w i工片ii ^ 丢 m 33 I h rr: uj 4j ,ΨΛττ .^ i± W M '^u t. i XL m icK bL ^ ...哗 迫 v ~m 其 m 旦 rf-l· i±± J^L itu pq α τ ±n ±± tJl ΕΕί -4-ft-i CD -£?p iJll用安S iB 式包含 A VT 3* O Si表面 mae ^i_ 4-ί<κ·. m jb m rriiri· & φ^4- 昭 J>C ί工 ίϊ*τ ί志 ·、.+ W f4C; i±. m m 3 8 8 3 ό 0 7顯不]史周油以反酒1¾ 媒介物。棍據lit專利寨,商業上可提 溶疲包含徹欖油,酒精和當作表面活 f i 1®。但是&配方會留下問題。 審通常有一令入不悅的氣祿和/或祿 不飽和脂詰酸的油容易腐敗c 的配方中須要相對之高含量的酒精。 對小孩施用此產品上會造成®難,並 這個目的而使用瑱充膠囊時,必須増 完成的精心工作。 案2 ,222 ,770的新頴劑量形 產品至溶液狀的途徑。這些系統包括 一有活性組成物,親脂性,親水性層 雜条統ϋ ifc形態的系統會造成交互反 所使羯的其中一種物質對病入衙言非 水溶液系統内的溶液中的目的。它們至少包含四個 ,名稱為活注組成物,植物油,酒精和一種表®活 國專利案4, -W- KA?衣占丨 /r*^* AtJ~r 六檢_连::¾ d li 飲羯的環孢靈 X 1 D ii L a d r a 表面活搜媒介 it之外,含有 -V, -T^ £rr Ziv 久,tt包3個 高酒精含量在 -fcr AAt RR 3¾ · 龅仔P li问邊 ϋ 為了避免蒸發 泡包装法包装 露在G Β專利 由微、?L跋觀&勺 個成份,形成 活性物質的複 的增加,Μ及 的危機之增加。 國專利案39 ,24,207掲露一生產施用靜腿 羯的樣疋水搭液m注射丨谷液之過程,其中 )Μ重量計一份的環孢靈 木紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -------*--------I 一 492876 A7 B7 五、發明說明(3 b ) K重量計8至1 3份的一或多種單詣飽和羥脂W 酸及聚乙二醇和 羥醇混合 ••it/· -r- tJ_ 1¾ 不叙土 m is ^ 讲乂 m ⑽河 所有 f 工本 r/j V 上小 在一起 產td和 破壞生 商業上 油,小 Μ及一或多種漬 計1至 _ fLL u i± Mi 研究。 鶴可利 -qpr Λθ 5:ιϊ 口」符ΐ·ϋ 麥油, :在7!挪 Ϊ ^Jrs 如C Y - -fr LL^ ϋ 之 ίχ: 士 人 £^¥3 t±^ ϋ: 一漶疋 的釋放特 用超音波 _行是圍 成_量形 tK傲 ;&為 口」 X、)上 2¾ a ) f^)-x rs -Tit? wj m m m b ) A ·/ V ri / A 製藥形 及徵· kxL· , i士 1± u ia 生成無 難的ύ 式是較 本發明 飲用溶 提及的 Μ重量 當作活 Μ重量 式是特 顆粒的 些形式 溶劑正 它同樣 不適合 驁奇的 疲或膠 hr 日 S ~zrf 问起KJ 計〇 * iOJL ί/\ Ί *± )136 m 計6至 3汾的 專利寨 為了周 OH .liL· · nj ι± -的劑量 玉米油 單或聚 a 及特別 別遺當 彤式並 戸 典 士入 w π < 菱形结 ί£顯示 的。 發現具 囊型式 Γ I Λ77 >j\ m m 5至2 1個或多個 和/或聚一 内能葰用來□服的製藥形式: 水稀釋這些配方,環孢靈沈 型式包括油性,親脂的組成 nja 單 …或二 羥醇類 甘油IS ) 0 5 4專利寨运明结晶xKj 是 CY-Α/Χ-ί I I , 的。這些配方說包含環孢靈 且有更好的穩定性或更良好 局部皮膚或局部眼睛使周。 晶形式的方法在企業層次上 無故定形式的環孢靈對於生 簡單組成和高生_可利用S 之□服施用的環孢靈劑量形 法,其包含: ,最好是1份的多個無晶形
5份的IS和的C (請先閱讀背面之注意事項再填寫本頁) 訂---- -線! 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 492876 A7 _B7 —…_ 五、發明說明(屮) ;-、 0至C 2 2 S脂肪駿之一或多種聚乙二醇單i旨;最好是S 0 L U T 0 L © HS 15,g[3 聚乙二醇一660 — 12-(證基)一硬脂酸酷, c ) K重量計 1 至3 ,最好是2份的一或多種單或多 羥醇當作共溶劑,最好是乙醇和丙二醇環孢靈的溶解度相 當地增加,特別是K水稀釋而維持著這些量特定的比例時 0 這遷不能正常迆被假定因為劑量型式使周脂肪酸的聚 乙二醉s§只當作疏水層和親水層間額外的溶解質。 因此所有入對於如tt的一種配方能顯示商業產品的生 物平衡大為驚訝(見上方)。 實際上,它無法預言如此的一個簡單而無親脂成汾的 配方能夠達到茹tt高的生锪可利周性。 更進一*步發現M D服施用力式精羅地使用無晶形的 S靈,盈環孢靈含量大於5 %的配方,可造成相當好的溶 液特性,經水稀釋後仍能讓持為一穩定,清澈的溶液。 因此,本發明係關於口服劑量形式,為可飲用溶疲或 是包裝在膠囊内,均包括K下成份在K下的比例:
a) Μ重量計0 + 5至2 ,最好是1份的一或多個環 孢靈,特別是Μ無晶彩被使用的環孢靈Α或G fa ) Μ重量計6至9 ,最好是7 * 5份的飽和的C 1 0至C 2 2羥脂訪駿之一或多種聚乙二醇單酷;最好是S 0LUT0L® HS 15 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ^ ·ϋ 1 ·ϋ II 1-1 一 ov a n I n I m Λ/Μβ ϋ I n i r— — — — — — — 492876 A7 _B7 _ —_ 五、發明說明(/ ) C )以重量計1至3 ,最好是2份的一或多種覃或多 羥醇當作共溶劑,最好是乙醇和丙二醇 根:據本發明,在生產的過程中,必須小心量的比例要 讓持,並且環孢靈一開始即要在室溫下持續攪拌使之完全 溶解於酒精内,隨後在仍為室溫攪择下SO入丙二醇和S 〇丨u t ο 1⑬ H S 1 5。過程產生的溶液包含 每毫升1 0 0毫克的活性成份。K可歆周溶疲或膠囊形 式完成是在一已知的影式下進行,例5D在每個膠囊肉包含 100毫克,50毫克或25毫克的活性組成物。 棍據本發明之組成的生產在下面實洌中詳IS說明 : 袖:/£;ϊϊ 1 1 0 0公克非固定形式的環孢靈A在室溫下S浮而溶 於1 27毫升的酒精内。隨後,進一步再於室溫下攪拌, 加入9 6毫升的丙二醇。得到一環孢靈A清激溶液之後, 入7 5 0公克的S o i u t o i ® H S 1 5並進一 步攪拌。可得到一澄漬、黏稠包含每毫升1 00毫克環孢 靈A的溶液。 在實例1中所升成的環孢靈A溶液甩水Ml :40的 比例稀釋。所彤成的溶疲可維持數個月的漬澈和穩定。 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ▼-------訂-------·!線!

Claims (1)

  1. 492876 -, A8 ; ' Ί :. B8 :/.、 入C8 、 D8 — —— ~— f ' 七、申請專利範圍 丨乂Γ ^, (請先閲讀背面之注意事項再填寫本頁) 1 * 一種□服環ίΜ靈藥學組成物,其為哥飲用溶液或 ®囊影式,包含: a ) Μ重量計0 + 5至2份的一或多種無晶形環JS靈 當作活性成汾 D ) 从重量 §十 b 主 0 1方 u'j C 1 0 至匕 ε 2 證,§§ 3® 酸 《ί! 一或多種聚乙二醇單iS c) Μ重量計1至3份的一或多種翬或多羥醇當诈共 溶Si。 2 *根據帛請專利範圍第1項的藥擧組成物,使甩非 晶形環孢靈A或環孢靈G當作活性成份。 3 * —種製儀□跟環孢靈藥學組成物的方法,該藥學 組成物為可飲用溶疲或膠囊形式,苜先在室溫下攪拌 a) 每1 00公克無晶形環孢靈,溶於1 27毫升的 酒精内 b) 又當在室溫下攪拌時,加入96毫升的丙二醇, 隱後又於室溫下攪拌, c )加入750公克的聚乙二醇—660— 1 2 —( 羥基)-硬脂酸脂,成為一清澈,黏稠的環孢靈溶液,並 Μ已茹的方式裝Μ成為可飮用的溶液或是包裝成為膠囊。 4 +如串請專利範圍第1項之藥學組成物,其包含Μ 重量計1份之一或多種無晶形環孢靈。 5 ♦如Φ譆專利範圍第1項之藥學組成物,其包含Μ 7 . 5份之飽和C 1 0至C 2 2羥脂訪酸之一或多種聚乙二 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 492876 A8 B8 C8 D8 六、申請專利範圍 醇覃酯。 (請先閲讀背面之注意事項再填寫本頁) 6 ▲ 50串請專利範圍第1項之藥學組成物,其包含Μ 重量計2扮的一或多種單或多證醇。 7 ♦如串請專利範圍第1項之藥學組成物,其中C 1 0至C 2 2羥脂肪酸之一或多種聚乙二醇覃酯為聚乙二 醇一660—12— (羥基)—硬脂酸脂 8 *如Φ請專利範圍第1項之藥學組成物,其中輋或 多羥醇為乙醇及/或两二醇 9 * Φ請專利範圍第3項之的方法 5 其中無晶彩環 孢靈為環孢靈A。 1 〇 +如串請專利範圍第1項之藥學組成物,其為膠 ir.< —p. . m n> is, ^ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
TW084108225A 1994-11-03 1995-08-08 New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture TW492876B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4438861 1994-11-03

Publications (1)

Publication Number Publication Date
TW492876B true TW492876B (en) 2002-07-01

Family

ID=6532126

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084108225A TW492876B (en) 1994-11-03 1995-08-08 New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture

Country Status (27)

Country Link
US (1) US6486124B2 (zh)
EP (1) EP0789580B1 (zh)
JP (1) JP3833248B2 (zh)
KR (1) KR970704464A (zh)
CN (1) CN1121238C (zh)
AT (1) ATE218359T1 (zh)
AU (1) AU715165B2 (zh)
BG (1) BG62955B1 (zh)
BR (1) BR9509550A (zh)
CA (1) CA2231404C (zh)
CZ (1) CZ287806B6 (zh)
DE (2) DE59510233D1 (zh)
DK (1) DK0789580T3 (zh)
EE (1) EE03425B1 (zh)
ES (1) ES2177652T3 (zh)
FI (1) FI118722B (zh)
HU (1) HUT77283A (zh)
LT (1) LT4306B (zh)
LV (1) LV11884B (zh)
NO (1) NO970741L (zh)
PL (1) PL183579B1 (zh)
PT (1) PT789580E (zh)
RU (1) RU2158601C2 (zh)
SK (1) SK164796A3 (zh)
TR (1) TR199501361A2 (zh)
TW (1) TW492876B (zh)
WO (1) WO1996014079A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2177652T3 (es) 1994-11-03 2002-12-16 Novartis Ag Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
ATE263550T1 (de) * 1995-08-25 2004-04-15 Sangstat Medical Corp Orale cyclosporinformulierungen
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
AU762247B2 (en) * 1997-01-30 2003-06-19 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
RU2211047C2 (ru) 1997-01-30 2003-08-27 Новартис Аг Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6506742B2 (en) 1999-12-13 2003-01-14 Ortho-Mcneil Pharmaceutical, Inc. Soluble contraceptive liquid formulation
EP1578787B1 (en) 2002-12-02 2012-11-14 Xenome Ltd Novel chi-conotoxin peptides (-ii)
JP4565087B2 (ja) 2002-12-02 2010-10-20 ゼノム リミティッド 新規なχ−コノトキシン・ペプチド(−I)
SE0301119D0 (sv) * 2003-04-14 2003-04-14 Astrazeneca Ab New non-ionic surfactants for solubilizing poorly soluble molecules
WO2005016312A1 (en) 2003-08-13 2005-02-24 Nobex Corporation Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
AU2006235478B2 (en) 2005-04-12 2011-07-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
DK2779994T3 (da) * 2011-11-15 2020-05-18 Allergan Inc Suspensioner af cyclosporin a form 2
WO2013074608A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Cyclosporine a form 2 and method of making same

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
GB1171125A (en) 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US3813345A (en) 1971-08-05 1974-05-28 Vanguard Chem Co Inc Method of producing microcolloidal aqueous emulsions of unsaturated organic compounds
US3954967A (en) 1971-08-05 1976-05-04 Vanguard Chemical Company, Inc. Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds
DE2455859C2 (de) 1973-12-06 1983-12-15 Sandoz-Patent-GmbH, 7850 Lörrach Das Antibiotikum Cyclosporin A (S 7481/F-1), seine Herstellung und Verwendung
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US4146499A (en) 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
JPS53107408A (en) 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH636013A5 (en) 1978-03-07 1983-05-13 Sandoz Ag More readily absorbable pharmaceutical composition
CH641356A5 (en) 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
AU558155B2 (en) 1982-02-01 1987-01-22 Sandoz Ltd. Treating multiple sclerosis with dihydro-cyclosporin d
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
DE3235612A1 (de) 1982-09-25 1984-03-29 Bayer Ag, 5090 Leverkusen Mikroemulsionen
DE3237814A1 (de) 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
DE3315805A1 (de) 1983-04-30 1984-11-08 Bayer Ag, 5090 Leverkusen Wirkstoffzubereitungen
JPS6061535A (ja) 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト 製薬学的組成物
FR2553661B1 (fr) 1983-10-19 1985-12-20 Rhone Poulenc Sante Nouvelles microemulsions pharmaceutiquement acceptables
DE3406497A1 (de) 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
GB8903804D0 (en) 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
EP0365044A3 (en) 1984-08-02 1990-08-22 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine
CH662944A5 (it) 1984-10-18 1987-11-13 Pier Luigi Prof Dr Luisi Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione.
JPS61280435A (ja) 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤
JPS61249918A (ja) 1985-04-26 1986-11-07 Yutaka Mizushima 点眼剤
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4797272A (en) 1985-11-15 1989-01-10 Eli Lilly And Company Water-in-oil microemulsions for cosmetic uses
SE457693B (sv) 1986-07-01 1989-01-23 Drilletten Ab Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas
EP0256856A3 (en) 1986-08-14 1989-01-11 Synthetic Blood Corporation A parenterally administrable composition
DE3629386A1 (de) 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
DE3707711A1 (de) 1987-03-11 1988-09-22 Hoechst Ag Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung
CA1301642C (en) 1987-03-30 1992-05-26 Howard Bernard Dawson Chemical formulations
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
ATE95193T1 (de) 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
GB2206119B (en) 1987-06-22 1990-10-31 Merck & Co Inc A new cyclosporin derivative with modified "8-amino acid"
US4835002A (en) 1987-07-10 1989-05-30 Wolf Peter A Microemulsions of oil in water and alcohol
HU205010B (en) 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
HU203564B (en) 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
EP0327280B1 (en) 1988-01-29 1992-03-18 Sankyo Company Limited Cyclosporin compositions
CH679119A5 (zh) 1988-05-13 1991-12-31 Sandoz Ag
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
EP0361928B1 (en) 1988-09-29 1994-04-27 Shiseido Company Limited Emulsified composition
CH679210A5 (zh) 1988-10-26 1992-01-15 Sandoz Ag
AU5157590A (en) 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration
GB2230440B (en) 1989-02-09 1993-05-19 Sandoz Ltd Novel cyclosporin galenic forms
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5177110A (en) 1989-10-27 1993-01-05 Ciba-Geigy Corporation Injectable parasiticidal composition
HU207222B (en) 1990-02-15 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing eyedrops containing primycin
US5260301A (en) 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
HU208491B (en) 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
EP0589843B1 (en) 1992-09-25 2001-11-28 Novartis AG Pharmaceutical compositions containing cyclosporins
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
IL111003A0 (en) 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
DE59409088D1 (de) 1994-10-04 2000-02-24 Lohmann Rudolf Lomapharm Lösungen von Anthrachinonen zur parenteralen Applikation
ES2177652T3 (es) 1994-11-03 2002-12-16 Novartis Ag Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.

Also Published As

Publication number Publication date
EE03425B1 (et) 2001-06-15
AU2975195A (en) 1996-05-31
CA2231404C (en) 2009-02-17
US6486124B2 (en) 2002-11-26
LV11884B (lv) 1998-03-20
TR199501361A2 (tr) 1996-06-21
RU2158601C2 (ru) 2000-11-10
CZ287806B6 (en) 2001-02-14
HUT77283A (hu) 1998-03-30
JPH10508306A (ja) 1998-08-18
LT97002A (en) 1997-11-25
EE9700112A (et) 1997-12-15
FI970634A0 (fi) 1997-02-14
LT4306B (lt) 1998-03-25
AU715165B2 (en) 2000-01-20
CN1121238C (zh) 2003-09-17
DE59510233D1 (de) 2002-07-11
FI118722B (fi) 2008-02-29
BR9509550A (pt) 1997-09-16
BG101117A (en) 1997-08-29
JP3833248B2 (ja) 2006-10-11
NO970741D0 (no) 1997-02-18
ATE218359T1 (de) 2002-06-15
BG62955B1 (bg) 2000-12-29
PL318560A1 (en) 1997-06-23
CA2231404A1 (en) 1996-05-17
PT789580E (pt) 2002-09-30
PL183579B1 (pl) 2002-06-28
DE19539860A1 (de) 1996-05-09
NO970741L (no) 1997-02-18
EP0789580A1 (de) 1997-08-20
FI970634A (fi) 1997-02-14
CN1162265A (zh) 1997-10-15
WO1996014079A1 (de) 1996-05-17
SK164796A3 (en) 1997-06-04
KR970704464A (ko) 1997-09-06
DK0789580T3 (da) 2002-09-09
EP0789580B1 (de) 2002-06-05
LV11884A (lv) 1997-12-20
CZ361696A3 (en) 1997-07-16
US20020025927A1 (en) 2002-02-28
ES2177652T3 (es) 2002-12-16

Similar Documents

Publication Publication Date Title
TW492876B (en) New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture
TW205035B (zh)
TW587936B (en) Pharmaceutical composition containing proton pump inhibitors
JP4170386B2 (ja) 疎水性薬剤の投与システム
ES2200048T3 (es) Composicion farmaceutica que contiene fenofibrato y gliceridos poliglicolizados.
TWI243060B (en) Dispersion formulations containing lipase inhibitors
ES2226976T3 (es) Formulaciones galenicas de fenofibrato y su procedimiento de obtencion.
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
MX2010013203A (es) Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona.
JPH03200728A (ja) 医薬組成物
CN106999558A (zh) (17‑β)‑3‑氧雄甾‑4‑烯‑17‑基十一酸酯组合物及其制备方法和用途
US4397835A (en) Enterosoluble hard-capsulated medicaments
TW455491B (en) Pharmaceutical composition for oral administration
Sarojini et al. Oral medicated jellies–a review
WO2003101378A2 (en) Pharmaceutical formulation in a drug delivery system and process for preparing the same
EP2036575B1 (en) Pharmaceutical compositions for oral use for treating patients affected by obesity
WO2005007070A2 (en) Stable pharmaceutical composition
JP7335256B2 (ja) シメチコン及びロペラミドのエマルションの医薬製剤
JP3277735B2 (ja) ナフトエ酸誘導体の吸収促進組成物
US7632853B2 (en) Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof
US20050175686A1 (en) Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
KR102770132B1 (ko) 시메티콘 및 로페라미드의 에멀션을 위한 약제학적 제형
TW528596B (en) Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors
WO2014135965A1 (en) Bismuth liquid filled hard capsules
KR20240057565A (ko) 무메프랄을 함유하는 장내 유산균 증식 및 우울증 예방 또는 치료용 조성물